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The matrix metalloproteinases (MMPs) are endopeptidases which break down the extracellular matrix and regulate cytokine and
growth factor activity. Several MMPs have been implicated in the promotion of invasion and metastasis in a broad range of tumours
including urothelial carcinoma. In this study, RNA from 132 normal bladder and urothelial carcinoma specimens was profiled for each
of the 24 human MMPs, the four endogenous tissue inhibitors of MMPs (TIMPs) and several key growth factors and their receptors
using quantitative real time RT–PCR. Laser capture microdissection (LCM) of RNA from 22 tumour and 11 normal frozen sections
was performed allowing accurate RNA extraction from either stromal or epithelial compartments. This study confirms the over
expression in bladder tumour tissue of well-documented MMPs and highlights a range of MMPs which have not previously been
implicated in the development of urothelial cancer. In summary, MMP-2, MT1-MMP and the previously unreported MMP-28 were
very highly expressed in tumour samples while MMPs 1, 7, 9, 11, 15, 19 and 23 were highly expressed. There was a significant positive
correlation between transcript expression and tumour grade for MMPs 1, 2, 8, 10, 11, 12, 13, 14, 15 and 28 (Po0.001). At the same
confidence interval, TIMP-1 and TIMP-3 also correlated with increasing tumour grade. LCM revealed that most highly expressed
MMPs are located primarily within the stromal compartment except MMP-13 which localised to the epithelial compartment. This
work forms the basis for further functional studies, which will help to confirm the MMPs as potential diagnostic and therapeutic
targets in early bladder cancer.
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Over 60240 new cases of urothelial carcinoma were diagnosed in
the United States in 2004, and bladder cancer is now the fourth
most common malignancy in males (Jemal et al, 2004). In the
United Kingdom, cancer of the urinary bladder accounted for
almost 5000 deaths in 2004. It is the fourth most common cancer
in men and the eighth most common in women (CRUK Cancer
Statistics, 2004).
Although the mortality associated with bladder cancer is
naturally of concern, most patients present with noninvasive
forms of the disease and with current treatment regimes, do not
die as a direct result of their malignancy. Over 75% of patients
present with one or more superficial tumours, and two thirds of
these will develop recurrent disease (Lutzeyer et al, 1982), with
10–20% progressing to an invasive phenotype (Torti and Lum,
1984). The outcome for patients with invasive disease at
presentation remains poor, with distant metastasis occurring in
over 50% within 2 years and an average 5-year survival of only
50% (Raghavan et al, 1990). The early identification of those
tumours likely to invade locally or to metastasize to distant sites
is key to optimising the diagnosis and treatment of urothelial
carcinoma.
The capacity to degrade and break down the basement
membrane and extracellular matrix is essential for primary tumour
cells to invade locally and spread to distant sites (Stamenkovic,
2000; Egeblad and Werb, 2002). The matrix metalloproteinases
(MMPs) comprise a family of 24 extracellular zinc dependent
endopeptidases with a broad spectrum of enzymatic activity
against all components of the extracellular matrix (ECM). There
are four primary endogenous tissue inhibitors of the MMPs
(TIMPs). The physiological functions of the MMPs and TIMPs
include organogenesis, tissue repair and wound healing (Vihinen
and Kahari, 2002).
The patho-physiological roles of MMPs are, however, not
limited to direct degradation and remodelling of the ECM; they
are involved in angiogenesis, cell migration and proliferation,
modulation of the host immune response and in the regulation of
apoptosis (Chang and Werb, 2001). It is, therefore, understandable
that members of the MMP family contribute to a number of disease
processes including arthritis, atherosclerosis and cancer (Birkedal-
Hansen et al, 1993). The evidence implicating MMPs in the
progression and metastasis of visceral malignant disease is
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sextensive and compelling. In urothelial carcinoma several of the
well characterised MMPs, including MMP-2, MMP-9 and MT1-
MMP (MMP-14), demonstrate increased expression and activity
(Raghavan et al, 1990; Davies et al, 1993; Kanda et al, 2000; Hara
et al, 2001).
It is evident that MMPs and TIMPs interact in a complex
manner to regulate the extracellular microenvironment. Collec-
tively, the MMP family can degrade all components of the
extracellular matrix and there is significant overlap of substrate
specificity between each MMP (Sternlicht and Werb, 2001; Egeblad
and Werb, 2002). Many well-established MMPs have a broad
proteolytic activity; however, not all MMPs share this property –
recently isolated members such as MMP-28 appear to have only a
single identified substrate, and for others the substrate or
signalling pathway is unknown (Lohi et al, 2001).
While most MMPs are secreted, six membrane type MMPs
(MT-MMPs) are bound to the cell surface through a C terminal
sequence acting as either a type 1 transmembrane domain or as a
signal for GPI anchoring (Seiki, 2002). The membrane-bound
MMPs act on a broad spectrum of ECM substrates, and are also
involved in the activation of other secreted MMPs and tumouri-
genic factors. MT1-MMP, in a complex with TIMP-2, converts
pro-MMP-2 to the active form. With the probable exception of
MT4-MMP, the other membrane bound MMPs show similar
activity (Murphy et al, 1999). MT1-MMP is also responsible for the
activation of proMMP-13 either directly or via MMP-2 activation
(Knauper et al, 1997).
Consequently, some MMPs have been proposed as prognostic
markers and therapeutic targets (Vihinen and Kahari,
2002), though phase III clinical trials with MMP inhibitors in
advanced disease have shown disappointing results (Coussens
et al, 2002). We postulate that accurate targeting of appropriate
therapy to early, high-risk tumours may demonstrate significant
benefits.
This present study uses an established and well-validated
quantitative real time PCR assay to conduct a comprehensive
profile of the entire MMP and TIMP family in a large series of
human urothelial carcinoma samples. Laser capture microdissec-
tion is used to localise highly expressed MMP transcripts to either
stromal or urothelial tissue compartments.
MATERIALS AND METHODS
Tissue samples and RNA preparation
In all, 169 surgical specimens of primary urothelial cell carcinoma
were collected, either at cystectomy or trans-urethral resection,
and snap frozen in liquid nitrogen. Twenty specimens of normal
bladder urothelium were collected from areas of macroscopically
normal urothelium in patients with no evidence of urothelial
malignancy. Use of tissues for this study was approved by
Cambridgeshire Local Research Ethics Committee (Ref 03/018).
A total of 30 sections of 30mm were homogenised for RNA
extraction and two 7mm ‘sandwich’ sections adjacent to tissue used
for RNA extraction were sectioned, stained and assessed for
cellularity and tumour grade by an independent consultant uro-
histopathologist. Additionally, the sections were graded according
to the degree of inflammatory cell infiltration (low, moderate and
significant). Samples showing significant inflammatory cell con-
tamination were excluded.
Total RNA was extracted using TRI Reagentt (Sigma, Dorset,
UK), following the manufacturers protocol. RNEasy Minikitst
(Qiagen, Crawley, UK), including a DNase step, were used to
optimise RNA purity. Agilent 2100t total RNA bioanalysis was
performed. One microlitre of resuspended RNA from each sample
was applied to an RNA 6000 NanoLabChipt, and processed
according to manufacturer’s instructions. All chips and reagents
were sourced from Agilent Technologiest (West Lothian, UK).
Reverse transcription
Total RNA concentrations were determined using the Nanodropt
ND1000 spectrophotometer (Nyxor Biotech, Paris, France). One
microgram of total RNA was reverse transcribed with 2mg random
hexamers (Amersham) and Superscript 11 reverse transcriptase
(Invitrogen, Paisley, UK) in 20ml reactions according to the
manufacturers instructions. cDNA was then diluted 1:100 with
PCR grade water and stored at  201C.
Quantitative RT–PCR
For qPCR reactions, specific primers and probes for all human
MMPs and TIMPs, EGF-R, VEGF-A, EMMPRIN, MET, TGF-b and
RECK were designed as previously described (Nuttall et al, 2003).
For 18S amplification, TaqMan Ribosomal RNA Control Reagents
were purchased from Applied Biosystems, Warrington, UK. PCR
reactions were performed using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Warrington, UK) following
the manufacturers protocol. Reactions for 18S analyses were
performed in 25ml PCR volumes containing the equivalent of 1ng
of reverse transcribed RNA, 50% TaqMan universal PCR Master
Mix without UNG (Applied Biosystems, Warrington, UK), 200nM
each of the forward and reverse primers and 100nM of probe.
Amplification conditions were 2min at 501C, 10min at 951C and
then 40 cycles each consisting of 15s at 951C and 1min at 601C.
Reaction conditions for target gene amplification were as
described above and the equivalent of 5ng of reverse transcribed
RNA was used in each reaction.
To determine relative RNA levels within the samples, standard
curves for the PCR reactions were prepared from a series of two-
fold dilutions of cDNA covering the range 2–0.625ng of RNA for
the 18S reaction and 20–0.5ng of RNA for all target genes. The
ABI Prism 7700 measured changes in fluorescence levels through-
out the 40 cycle PCR reaction and generated a cycle threshold (CT)
value for each sample correlating to the point at which
amplification entered the exponential phase. This value was used
as an indicator of the amount of starting template; hence a lower
CT values indicated a higher amount of initial intact cDNA.
Laser capture microdissection
Tissue for laser capture microdissection was collected prospec-
tively following the procedure outlined above. In all, eleven normal
urothelial samples and 22 tumour samples were obtained. Five
sequential sections of 7mm thickness were cut from each tissue and
stained using Histogenet staining solution (Arcturus, California,
USA) following manufacturer’s protocol. Slides were then im-
mediately transferred for microdissection using a Pix Cell II laser
capture microscope (Arcturus, CA, USA). This technique employs
low-power infrared laser to melt a thermoplastic film over the cells
of interest, to which the cells become attached.
Approximately 10000 cells were microdissected from both
stromal and epithelial/tumour compartments in each tissue. RNA
was extracted using an RNEasy Micro Kit (Qiagen, Crawley, UK).
Areas of tumour or stroma containing significant inflammatory
cell infiltration were avoided to prevent contamination.
Total RNA was reverse transcribed and qRT–PCR performed as
above. Given the low yield of RNA from such small samples,
Nanodropt quantification was not performed, but correction for
the endogenous 18S CT value was used as an accurate measure of
the amount of intact starting RNA. Transcript analysis was
performed on the secreted MMPs 2, 9, 11, 13, the membrane
bound MMPs 14 and 15, and TIMP-2.
To validate the accuracy of microdissection, primers and probes
for Vimentin and Uroplakin were sourced and qRT–PCR
performed according to manufacturer’s instructions (Assays on
demand, Applied Biosystems, Warrington, UK). Vimentin is
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sprimarily expressed in mesenchymally derived cells, and was used
as a stromal marker. Uroplakin is a marker of urothelial
differentiation and is preserved in up to 90% of epithelially
derived tumours (Olsburgh et al, 2003).
Statistical analysis
RNA expression levels for each target gene were normalised to the
endogenous 18S rRNA levels. For grade correlation studies, two-
tailed spearman’s Rank Correlation was performed to determine
the significance of the relationship between gene expression and
increasing tumour grade. To determine the significance of
differential expression in the laser captured tissue, a two-sided
Mann–Whitney U nonparametric analysis was performed, for
which a P-value of o0.05 was considered significant.
RESULTS
RNA quality control and PCR validation
After RNA assessment using the Nanodropt spectrophotometer,
Agilent 2100t Biolanalyser, and endogenous 18S rRNA gene, 113
tumours and 19 normal bladder specimens were considered to
have intact RNA and be suitable for analysis. In all, 14 tumours
were grade 1, 57 were grade 2 and 42 were grade 3. Primer and
probe sets had been optimised and validated as previously
described (Nuttall et al, 2003).
Expression levels of MMPs and TIMPs in human bladder
tissue
The PCR cycle threshold (CT) was used to quantify the expression
of each gene in a given sample. Genes with CT values of o26 cycles
were considered to be very highly expressed, those with values of
26p30 cycles were highly expressed, 30p35 cycles moderately
expressed and genes with CT values in the range 35p40 low or
absent. Table 1 shows the relative expression levels for each gene of
interest in all bladder tumour samples.
In summary, MMP-2, MT1-MMP and the previously unreported
MMP-28 were very highly expressed in tumour samples. MMPs 1,
7, 9, 11, 15, 19 and 23 were highly expressed while there was
moderate expression of MMPs 3, 10, 12, 13, 16, 17, 24 and 25, and
low expression of MMPs 8, 21, 26 and 27. No MMP-20 (enamel-
ysin) RNA transcripts were detected in any bladder tissue. Analysis
of the TIMPs confirmed very high expression of TIMP-1 and
TIMP-3 and high expression of TIMP-2 and TIMP-4. EMMPRIN
and VEGF-A showed a very high expression profile, with MET,
TGF-b, and EGF-R highly expressed.
Correlation of MMPs, TIMPs, and growth factor expression
with tumour grade
After normalisation of CT values to individual standard curves for
each gene of interest, relative RNA expression values were
generated which allowed comparison of gene expression between
the groups of normal tissue, low grade (grade 1), intermediate
(grade 2) and high grade (grade 3) tumour tissue. The relationship
between MMPs which were classified as very highly or highly
expressed and tumour grade is represented in Figure 1 and that for
key TIMPs, growth factors and receptors in Figure 2.
There was a significant positive correlation between transcript
expression and tumour grade for MMPs 1, 2, 8, 10, 11, 12, 13, 14, 15
and 28 (Po0.001). At the same confidence interval, TIMP-1 and
TIMP-3 also correlated with increasing tumour grade.
The growth factors and receptor genes EMMRIN, MET, TGF-b,
VEGF-A and EGF-R all demonstrated highly significant positive
correlations with tumour grade (Po0.001). Expression levels of the
metalloproteinase inhibitor RECK were lower in all grades of
tumour tissue than in normal tissue, but the relationship did not
achieve statistical significance.
Laser capture microdissection
The MMP genes that demonstrated both high expression and
significant positive correlation with increasing tumour grade were
then investigated using laser capture microdissection (LCM). RNA
yields were in the region 50–80ng for the laser capture of 10000
cells, and RNA was well preserved, with endogenous 18S CT values
clustering closely around 15 cycles. Figure 3 summarises the
results of this study.
The stromal marker gene vimentin and the epithelial marker
uroplakin confirmed accurate microdissection of discrete cell
populations. Vimentin expression was significantly higher in the
stromal compartment in both normal tissue (Po0.05) and tumour
tissue (Po0.001). Uroplakin RNA expression was significantly
higher in the tumour compartment of normal tissue (Po0.01) and
tumour tissue (Po0.001).
Independent of compartmental analysis, several target genes
showed fold differences in expression between normal and tumour
tissue which matched closely those observed in the gross profiling
study. MMP-9 and MMP-28 appeared evenly distributed between
stromal and epithelial compartments. In tumour tissues, MMPs 2,
11, 14, 15 and TIMP-2 were expressed at a significantly higher level
in stromal tissue when compared to tissue from the epithelially
derived compartment (Po0.05). MMP-13 was the only target gene
to localise preferentially to the epithelial compartment (Po0.05).
DISCUSSION
It is accepted that no single chromosomal insult, no individual
protein or indeed family of proteins, can be held uniquely
Table 1 Relative RNA transcript expression (expressed as mean CT
value) for all MMPs, TIMPs, EMMPRIN, MET, RECK, VEGF-A, TGF and
EGF-R in bladder tumour tissue (n¼113)
Target gene Expression level Target gene Expression level
MMP-1 28.2 MMP-23 29.8
MMP-2 22.5 MMP-24 33.2
MMP-3 31.3 MMP-25 33.2
MMP-7 27.6 MMP-26 38.7
MMP-8 38.5 MMP-27 36.2
MMP-9 29.2 MMP-28 26.5
MMP-10 30.2 TIMP-1 22.5
MMP-11 27 TIMP-2 28.2
MMP-12 30.4 TIMP-3 23.5
MMP-13 31.1 TIMP-4 31.5
MMP-14 24.7
MMP-15 26.6 EMMPRIN 25.8
MMP-16 32.9 MET 27.8
MMP-17 33.4 RECK 30.4
MMP-19 28.5 VEGF-A 23.9
MMP-20 40 TGF 28.8
MMP-21 35.8 EGF-R 26.3
Expression level Mean CT value
Low 35o39
Moderate 30o35
High 26o30
Very high o26
Genes with CT values of p25 cycles were considered to be very highly expressed,
those with values of 26p30 cycles were highly expressed, 30p35 cycles moderately
expressed and genes with CT values in the range 35p40 low or absent.
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sresponsible for the transition from steady-state proliferating,
regenerating epithelial cells to a high grade, invasive tumour
phenotype. The process is complex, requiring a temporal or spatial
combination of tumourigenic events. Matrix metalloproteinases,
by virtue of their diverse spectrum of activity, are likely to play key
roles in many of these biological processes.
MMPs have been implicated in angiogenesis, either directly or
via the upregulation or activation of pro-angiogenic factors such as
VEGF (Bergers et al, 2000; Sounni et al, 2002) and in the case of
MT1-MMP there is recent evidence that this regulation may occur
at a transcriptional level (Sounni et al, 2004). However, not all
MMP activity is proangiogenic; for example the gelatinases and
MMP-7 can cleave plasminogen to form the angiogenesis inhibitor
angiostatin (Cornelius et al, 1998).
MMPs 7 and 11 are involved in apoptotic regulation through
several pathways including FAS death receptor ligand cleavage and
HB-EGF activation (Mitsiades et al, 2001; Wu et al, 2001; Yu et al,
2002). Additionally, MMPs cleave cell adhesion molecules such as
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Figure 1 Relative mRNA expression for MMPs 1, 2, 10, 11, 12, 13, 14, 15, 19 and 28 in 19 normal tissue, 14 grade 1(G1), 57 grade 2 (G2) and 42 grade 3
(G3) tumours. RNA expression for each target gene is normalised to the endogenous 18S value for each sample, giving a relative expression value, which
allows intragene comparison. Median values are denoted by a horizontal line. Spearman Rank Correlation coefficients are shown for each gene, along with
P-value.
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sE cadherin (Lochter et al, 1997), and modulate the immune
response to tumours through chemokine deactivation (McQuibban
et al, 2000, 2001, 2002) and T-lymphocyte suppression (Sheu et al,
2001).
This work represents the first comprehensive quantitative RNA
transcript profile of the entire MMP and TIMP family in a large
cohort of human bladder tumours. Quantitative RT–PCR is
accurate, with high specificity and sensitivity, registering the
equivalent of o1 mRNA transcript per cell. The robust nature of
this technique is evidenced within this study. We observed similar
fold differences in MMP expression between normal and tumour
tissue in both the 132 gross profiling samples and the 31 tissue
sections used for microdissection. These two tissue cohorts were
processed identically but at different times, and originated from
two entirely different patient populations.
This analysis confirms the importance of well-documented
MMPs, but also highlights elevated expression and correlation with
increasing tumour grade for novel genes, which represent
interesting targets for further analysis. In general, we observed
that low-grade (G1) tumours show expression patterns similar to
normal tissue, independent of tumour stage. If analysis is
restricted to non-invasive stage pTa/pT1 tumours, for all MMPs,
the correlation with increasing grade remains significant (data not
shown).
In urothelial cell carcinoma, in common with most disease
processes, the most widely documented MMPs are the gelatinases
(MMPs 2 and 9), which have been shown to correlate with
increasing tumour grade using techniques such as quantitative
zymography (Davies et al, 1993; Kanda et al, 2000). MMP-2
expression was significantly higher in muscle invasive disease
when analysed by semi quantitative RT–PCR (Kanayama et al,
1998; Xu et al, 2002) and immunohistochemistry (Sumi et al,
2003). In this study, MMP-2 was confirmed as being very highly
expressed in tumour tissue, and to correlate significantly with
increasing tumour grade. MMP-2 upregulation may well represent
an exaggerated host response, as LCM analysis confirmed that
RNA transcripts are located primarily in the host stroma rather
than epithelially derived tumour cells. It is likely that RNA
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stage (See legend for Figure 1).
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stranscript localisation accurately reflect protein expression, as
similar distributions have been noted in bladder with immuno-
histochemistry (Sumi et al, 2003).
In a series of 51 superficial bladder cancers, MMP-9 RNA
expression was 2.5 fold higher in the tumours of patients with
subsequent recurrence (Hara et al, 2001); we have shown that,
while highly expressed in tumour tissue, MMP-9 just failed to
demonstrate a significant correlation with tumour grade or to
localise to a specific tumour compartment. This may reflect the
complex balance between pro- and antitumourigenic activity of
several MMPs and their endogenous inhibitors (Egeblad and
Werb, 2002).
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Uroplakin Vimentin
MMP-2 MMP-9
MMP-11 MMP-13
MMP-14 MMP-15
MMP-28 TIMP-2
P=0.94 P<0.01
NS NE TS TE
P=0.84 P<0.05
NS NE TS TE
P=0.32 P<0.05
NS NE TS TE
P=0.9 P=0.6
NS NE TS TE
P=0.09 P<0.05
NS NE TS TE
P=0.07 P<0.05
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P<0.05 P<0.05
NS NE TS TE
P<0.001 P<0.01
NS NE TS TE
P<0.001 P<0.01
NS NE TS TE
P=0.8 P=0.09
Figure 3 Relative RNA Expression for normal stroma (NS), normal epithelium (NE), tumour stroma (TS) and tumour epithelium (TE). Uroplakin and
vimentin are epithelial and stromal validation markers respectively. Target genes are MMP-2, 9, 11, 13, 14, 15 and 28 and TIMP-2. Mann Whitney
nonparametric test was used to detect significant differences between stromal and epithelial compartments. Significant differences (Po0.05) are highlighted
in bold, and median values are denoted by a horizontal line.
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importance of other MMPs in bladder cancer. The concentration of
MMP-1 in urine correlates with tumour stage and grade (Nutt et al,
1998; Durkan et al, 2001), a relationship confirmed in tissue
samples in our study. Using immunohistochemistry, Nakopoulou
et al (2001) showed MMP-1 and MMP-3 to be overexpressed in
bladder tumour tissue, with only the former showing a positive
correlation with either stage or grade. Our profiling verified that
MMP3 was only moderately expressed in normal and tumour
tissue, with no relationship with increasing grade. Other protei-
nases, such as MMP-7, 11 and 13 have been detected in increased
levels in bladder cancers, but have in general failed to demonstrate
statistically significant positive relationships with pathological end
points (Bostrom et al, 2000; Mueller et al, 2000; Sumi et al, 2003).
We have demonstrated that the secreted MMPs 10–13 inclusive all
show significant positive correlation with tumour grade. Micro-
dissection revealed that MMP-11 was located primarily in the host
stroma; in concordance, Mueller et al (2000) localised MMP-11
protein to peritumour fibroblasts in breast and bladder cancer.
However, MMP-13 was the only proteinase in our study to localise
to the epithelially derived tumour component. Using in situ
hybridisation and immunohistochemistry, Bostrom et al (2000)
demonstrated MMP-13 RNA and protein localisation to the cells at
the leading edge of invading bladder tumours, a finding confirmed
in oesophageal tumours by Etoh et al (2000).
Interestingly MMP-28, or epilysin, is very highly expressed in
bladder samples, especially in high-grade tumours. This protein
has been documented to be elevated in a number of human
malignancies including colonic adenocarcinoma and ovarian
carcinoma using nonquantitative PCR (Marchenko and Strongin,
2001). However, in contrast to these findings, Bister et al (2004)
have suggested that MMP-28 expression is reduced in colonic
cancer epithelium, when compared to normal tissue. To our
knowledge, MMP-28 has not previously been investigated in
bladder cancer.
Membrane bound MMPs are of increasing interest, although the
extent of their investigation in urothelial cancers is limited. MT1-
MMP (MMP-14) and MT2-MMP (MMP-15) both demonstrated an
extremely highly significant RNA expression profile in this study,
and localised to the tumour stroma. They have been shown to be of
interest in breast carcinoma with the former showing a distribu-
tion similar to MMP-2, and to correlate with increasing tumour
stage (Ueno et al, 1997). Elevated expression of MT1-MMP has
been reported in a variety of solid tumours including cervix (Gilles
et al, 1996), head and neck and colon (Okada et al, 1995). In tissues
from 41 patients with bladder cancer, using nonquantitative RT–
PCR, MT1-MMP was shown to associate strongly with decreased
survival (Kanayama et al, 1998). Nakahara et al (1997) observed
the preferential localisation and functional significance of MT1-
MMP in the invadopodia of melanoma cells. Localisation studies
suggest that stromally derived MT1-MMP may be cleaved from the
cell surface and that the resulting soluble protein is endocytosed
and re-expressed by the tumour cells (Chenard et al, 1999), but
this is currently unsubstantiated.
The endogenous TIMPs have a complex relationship with the
MMP family. While all four TIMPs inhibit most MMPs (with
the exception of TIMP-1 which has a limited inhibitory effect on
the membrane bound MMPs), they are also implicated in
protumourigenic activities including promotion of cell prolifera-
tion, apoptotic resistance and, in the case of TIMP-2, the activation
of latent MMP-2 in a complex with MT1-MMP (Baker et al, 2002).
We found TIMP-1, TIMP-2 and TIMP-3 to be highly expressed
both in normal tissue and in tumour tissue, with increased
expression in high-grade tumours. Similar patterns have been
reported in bladder, colorectal, breast and lung cancer (Grignon
et al, 1996; Kossakowska et al, 1996). Several reports have
postulated the MMP/TIMP ratio as significant in predicting either
tumour recurrence or progression in bladder cancer, concentrating
on MMPs 1, 2 and 9 and TIMPs 1 and 2 (Gohji et al, 1996; Durkan
et al, 2003). A rise in MMP/TIMP ratio may indicate a net increase
in proteolytic activity. Analysis of our profiling data shows an
increase in MMP/TIMP ratios for combinations of all the above
MMPs and TIMPs in high-grade tumours, suggesting a markedly
proteolytic microenvironment.
We also profiled mRNA transcript expression of several growth
factors and receptors implicated both in the upstream regulation
and downstream signalling pathways of the MMPs. The endo-
genous MMP inducer EMMPRIN stimulates stromal fibroblasts to
produce MMPs 1, 2 and 3 (Caudroy et al, 2002). It was expressed in
high levels in high-grade tumours in this study. Conversely, the
membrane anchored MMP inhibitor RECK (reversion inducing
cysteine-rich protein with kazal motifs) has been shown by
Takeuchi et al (2004) to correlate inversely with recurrence and
microvessel formation in colorectal cancer.
We confirmed that VEGF-A, TGFb, EGF-R and c-MET were all
highly expressed in tumour tissue, and correlated positively with
tumour grade. VEGF-A is upregulated by MT1-MMP promoting
angiogenesis, as discussed previously and TGF-b is a substrate of
the gelatinases. Once activated, it is involved in endothelial
proliferation and tubulogenesis (Stamenkovic, 2000). Evidence for
the importance of EGF-R in progression of epithelial tumours
including bladder cancer exits both in vivo and in vitro (Popov
et al, 2004). It has been shown to be highly expressed in high grade
bladder tumours using immunohistochemistry (Neal et al, 1990).
The Hepatocyte Growth Factor (HGF) receptor c-MET tyrosine
kinase is expressed on epithelially derived tumour cells, and is
involved in HGF mediated activation of both MMP2 and MT1-
MMP (Hamasuna et al, 1999).
Large-scale quantitative mRNA transcript profiling combined
with laser capture microdissection of specific tumour compart-
ments generates a powerful ‘snapshot view’ of gene expression in
normal and tumour tissues. While no true functional conclusions
can be drawn as to the roles of the MMPs TIMPs, growth factors or
receptors profiled, the upregulation of such a broad spectrum of
the MMP family suggests they are an integral part of the complex
pathways involved in bladder tumour progression. Studies have
demonstrated upregulation of multiple members of the MMP
family in other tumour types including prostate and glioblastoma,
but the expression patterns vary significantly between tissue types
(Nuttall et al, 2003; Riddick et al, 2005). In a recent study by
Martinez et al (2005), a wide spectrum of MMPs were found to be
upregulated in early murine colonic adenomas; those MMPs
located on chromosome 9 showed significantly greater upregula-
tion that those expressed on other chromosomes, suggesting a
shared regulatory mechanism resulting in coordinated deregula-
tion of expression in tumour tissue. Although the majority of the
chromosome 9 MMPs were shown to be upregulated in our study,
several, including MMPs 3, 8 and 10, demonstrated only moderate
or low expression, leaving the concept of chromosomal based
coregulation of MMP expression open to further debate.
Our work confirms the importance of well-documented genes,
such as MMP-2 and MT1-MMP, but also highlights several new
proteases including MMP-28, whose localisation and function in
early bladder cancer is under-investigated. Further protein based
and functional research will help to characterise the roles of these
newer proteinases and underline their potential as prognostic,
diagnostic or therapeutic markers in early bladder cancer.
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